" class="no-js "lang="en-US"> Levi Garraway - Medtech Alert
Saturday, May 11, 2024
Levi Garraway

Levi Garraway

About Levi Garraway

As the chief medical officer at Roche and Genentech, I lead global product development and work with highly talented and motivated teams from around the world. Together, we follow the science and pursue therapeutic breakthroughs that will help people with many types of challenging diseases.

Over the course of my career, I have worn the hats of the clinician, teacher, biomedical researcher, team builder, and drug development leader. My passion for bringing scientific advances forward to benefit patients ultimately led me to make the “jump” from academia to industry, where knowledge of disease biology is driving new therapeutic advances at an increasingly rapid rate.

Today, cutting-edge technologies and analytics are helping us both to gain a higher resolution understanding of disease and to develop medicines and solutions that enable more individualized care. At Roche and Genentech, our ultimate goal is to transform the bold vision of personalized healthcare into a reality for people everywhere.

Related Story

New Two-year Data Confirm Roche’s Vabysmo Improves Vision With Fewer Treatments for People With Neovascular Age-related Macular Degeneration

December 14 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the TENAYA and […]

European Commission Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss

September 20 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) approved Vabysmo® (faricimab) […]

FDA Accepts Supplemental Biologics License Application for Roche’s Polivy Combination for People With Previously Untreated Diffuse Large B-cell Lymphoma

August 16 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]

CHMP Recommends EU Approval of Roche’s Vabysmo, the First Bispecific Antibody for the Eye, for Two Leading Causes of Vision Loss

July 25 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]

European Commission Approves Roche’s Tecentriq as Adjuvant Treatment for a Subset of People With Early-stage Non-small Cell Lung Cancer

June 9 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) […]

European Commission Approves Roche’s First-in-class Bispecific Antibody Lunsumio for People With Relapsed or Refractory Follicular Lymphoma

June 8 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional […]

FDA Approves Roche’s Evrysdi for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)

May 31 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]

New Pivotal Data Demonstrate Clinical Benefit of Roche’s Glofitamab, a Potential First-in-class Bispecific Antibody for People With Aggressive Lymphoma

May 27 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on its investigational […]

Roche’s Polivy Combination Approved by European Commission for People With Previously Untreated Diffuse Large B-cell Lymphoma

May 26 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted […]

CHMP Recommends EU Approval of Roche’s Tecentriq as Adjuvant Treatment for a Subset of People with Early-stage Non-small Cell Lung Cancer

April 25 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]

U.S. FDA Grants Priority Review to Roche’s Actemra/Roactemra for the Treatment of COVID-19 in Hospitalised Adults

April 4 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]

Ad Hoc Announcement Pursuant to Art. 53 Lr Roche Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-stage Small Cell Lung Cancer

March 30 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III SKYSCRAPER-02 study, evaluating the […]

New Data for Roche’s Evrysdi (risdiplam) Demonstrate Long-term Efficacy and Safety in a Broad Population of People with Spinal Muscular Atrophy (SMA)

March 16 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for Evrysdi® (risdiplam) in spinal muscular atrophy […]

New Two-year Data for Roche’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision with Fewer Treatments for People with Two Leading Causes of Vision Loss

February 11 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new two-year data from its phase […]

FDA Approves Roche’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

January 31 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]

Roche’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-symptomatic Babies Under 2 Months of Age with Spinal Muscular Atrophy (SMA)

January 25 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]

CHMP Recommends EU Approval of Actemra/RoActemra to Treat Patients with Severe COVID-19

December 7 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]

US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer

October 18 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration […]

FDA Accepts Application for Roche’s Faricimab for the Treatment of Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

July 29 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]

New Data for Roche’s Hemlibra Reinforce Safety Profile in People with Haemophilia A

July 19 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the […]

Roche’s ENSPRYNG Approved by European Commission as First and Only At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)

June 29 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved […]

New Roche Data for Evrysdi Show Improved Motor Function in Pre-symptomatic Babies after One Year

June 11 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new interim data from two studies of […]

European Commission Approves Venclyxto-based Combinations for Adults with Newly Diagnosed Acute Myeloid Leukaemia Who Are Ineligible for Intensive Chemotherapy

May 25 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto […]

Roche’s Tecentriq Approved by European Commission

May 5 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq […]

New Roche Data at 2021 AAN Highlight Neuroscience Portfolio

April 9 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and […]